Prostate Cancer

Co-X-Gene Technology Will Target Advanced, Hormone-Refractory Disease

Published in Gene Therapy Weekly, October 4th, 2001

Virax Holdings Ltd. (VHL) has entered into a collaborative agreement with Dr. Michael Brown of Royal Adelaide Hospital's Cancer Centre to develop leads for an immune-based therapy to treat prostate cancer.

The therapeutic vaccine to be developed under the agreement will use Virax's platform technology, Co-X-Gene in FPV (fowlpox virus) vector. The prostate cancer program represents an additional application for the technology, which is currently being used in phase I/IIa clinical trial testing Co-X-Gene in FPV for the treatment of HIV.

A short list of leads has been selected for the prostate cancer development program and will undergo testing to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-10-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry